pf-04620110
Small moleculeexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2008 (NCT00799006)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- DGAT1 proteinINHIBITOR
Q9BRH5 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Nc1ncnc2c1C(=O)N(c1ccc([C@H]3CC[C@H](CC(=O)O)CC3)cc1)CCO2- Mol. weight
- 396.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1835919 ↗
Also known as
- pf-04620110
- pf-04620110
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01474941 | Phase 1 | Jun 1, 2011 | Pfizer |
| NCT01298518 | Phase 1 | Feb 1, 2011 | Pfizer |
| NCT01166217 | Phase 1 | Jul 1, 2010 | Bristol-Myers Squibb, Pfizer |
| NCT01146327 | Phase 1 | Jun 1, 2010 | Bristol-Myers Squibb, Pfizer |
| NCT01064492 | Phase 1 | Feb 1, 2010 | Pfizer |
| NCT00959426 | Phase 1 | Aug 1, 2009 | Bristol-Myers Squibb, Pfizer |
| NCT00799006 | Phase 1 | Nov 1, 2008 | Pfizer |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 7 | 7 | 1 | 2008 |
| Bristol-Myers Squibb | For profit | 3 | 0 | 1 | 2009 |
2 organizations
Page 1 / 1